Trifluoromethylphenylpiperazine

Use and effects

TFMPP is rarely used by itself. In fact, TFMPP reduces locomotor activity and produces aversive effects in animals rather than self-administration, which may explain the decision of the DEA not to permanently make TFMPP a controlled substance. More commonly, TFMPP is co-administered with BZP, which acts as a norepinephrine and dopamine releasing agent. Due to the serotonin agonist effects and increase in serotonin, norepinephrine, and dopamine levels produced by the BZP/TFMPP combination, this mixture of drugs produces effects which crudely mimic those of MDMA.

In a clinical study, TFMPP produced effects in humans including dysphoria, dextroamphetamine-like effects (i.e., stimulant-like effects), tension and anxiety, mental confusion and "bewilderment", and increased ratings of "drug liking", "high", and "stimulated". The drug has been anecdotally reported to produce mild psychedelic effects in humans, but no hallucinogenic effects with the drug were described in the study at the employed dose.

Side effects

The combination of BZP and TFMPP has been associated with a range of side effects, including insomnia, anxiety, nausea and vomiting, headaches and muscle aches which may resemble migraine, seizures, impotence, and rarely psychosis, as well as a prolonged and unpleasant hangover effect. These side effects tend to be significantly worsened when the BZP/TFMPP mix is consumed alongside alcohol, especially the headache, nausea, and hangover.

However, it is difficult to say how many of these side effects are produced by TFMPP itself, as it has rarely been marketed without BZP also being present, and all of the side effects mentioned are also produced by BZP (which has been sold as a single drug). Studies into other related piperazine drugs such as mCPP suggest that certain side effects such as anxiety, headache and nausea are common to all drugs of this class, and pills containing TFMPP are reported by users to produce comparatively more severe hangover effects than those containing only BZP. The drug can also cause the body to tremble for a long period of time.

Pharmacology

Pharmacodynamics

TFMPP has affinity for the 5-HT1A (Ki = 288–1,950 nM), 5-HT1B (Ki = 30–132 nM), 5-HT1D (Ki = 282 nM), 5-HT2A (Ki = 160–269 nM), and 5-HT2C (Ki = 62 nM) receptors, and functions as a full agonist at all sites except the 5-HT2A receptor, where it acts as a weak partial agonist or antagonist. Unlike the related piperazine compound meta-chlorophenylpiperazine (mCPP), TFMPP has insignificant affinity for the 5-HT3 receptor (IC50 = 2,373 nM). TFMPP also binds to the SERT (EC50 = 121 nM) and evokes the release of serotonin. It has no effects on dopamine or norepinephrine reuptake or efflux.

TFMPP has been found to reduce aggression in rodents. It produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and hence would be predicted to have hallucinogenic effects in humans. TFMPP was not self-administered by rhesus monkeys, suggesting that it lacks reinforcing effects.

Chemistry

Derivatives

• Antrafenine
• CPD-1

Society and culture

Legal status

Canada

Since 2012, TFMPP has been listed as a Schedule III controlled substance in Canada, making possession of TFMPP a federal offence. It has also been added to Part J of the Food and Drug Regulations thereby prohibiting the production, export or import of the substance.

China

As of October 2015 TFMPP is a controlled substance in China.

Denmark

As of December 3, 2005, TFMPP is illegal in Denmark.

Finland

Scheduled in government decree on psychoactive substances banned from the consumer market.

Japan

Since 2003, TFMPP and BZP became illegal in Japan.

Netherlands

TFMPP is unscheduled in the Netherlands.

New Zealand

Based on the recommendation of the EACD, the New Zealand government has passed legislation which placed BZP, along with the other piperazine derivatives TFMPP, mCPP, pFPP, MeOPP and MBZP, into Class C of the New Zealand Misuse of Drugs Act 1975. A ban was intended to come into effect in New Zealand on December 18, 2007, but the law change did not go through until the following year, and the sale of BZP and the other listed piperazines became illegal in New Zealand as of 1 April 2008. An amnesty for possession and usage of these drugs remained until October 2008, at which point they became completely illegal.

Sweden

As of March 1, 2006, TFMPP is scheduled as a "dangerous substance" in Sweden.

Switzerland

As of December 1, 2010, TFMPP is a controlled substance in Switzerland.

United Kingdom

As of December 2009, TFMPP has been made a Class C drug in the United Kingdom along with BZP.

United States

TFMPP is not currently scheduled at the federal level in the United States, but it was briefly emergency scheduled in Schedule I. The scheduling expired in April 2004 and was not renewed. However, some states such as Florida have banned the drug in their criminal statutes making its possession a felony.

Florida

TFMPP is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in Florida.

Texas

TFMPP is controlled in Texas under Penalty Group 2, as a hallucinogenic substance. It is illegal to possess TFMPP in any quantity in Texas.

References

References

1. Anvisa. (2023-07-24). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial". [[Diário Oficial da União]].
2. "Ustawa z dnia 15 kwietnia 2011 r. o zmianie ustawy o przeciwdziałaniu narkomanii ( Dz.U. 2011 nr 105 poz. 614 )". Internetowy System Aktów Prawnych.
3. "Erowid TFMPP Vault: Basics". Erowid.
4. (March 2011). "The clinical toxicology of the designer "party pills" benzylpiperazine and trifluoromethylphenylpiperazine". [[Clin Toxicol]].
5. (October 2006). "Interaction of amphetamines and related compounds at the vesicular monoamine transporter". Journal of Pharmacology and Experimental Therapeutics.
6. (November 2007). "MDMA-like behavioral effects of N-substituted piperazines in the mouse". Pharmacology Biochemistry and Behavior.
7. (August 2010). "Determining the subjective effects of TFMPP in human males". Psychopharmacology (Berl).
8. "Legal party pill use in New Zealand: Prevalence of use, availability, health harms and 'gateway effects' of benzylpiperazine (BZP) and trifluorophenylmethylpiperazine (TFMPP)". Centre for Social and Health Outcomes Research and Evaluation (SHORE).
9. "4-(Piperazin-1-yl)-2-(trifluoromethyl)phenol".
10. (March 2005). "N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy')". Neuropsychopharmacology.
11. (January 1987). "Central serotonin receptors as targets for drug research". J Med Chem.
12. (1992). "mCPP but not TFMPP is an antagonist at cardiac 5HT3 receptors". Life Sciences.
13. (October 1995). "Serotonin receptors and animal models of aggressive behavior". Pharmacopsychiatry.
14. (April 1995). "Effects of selective serotonergic agonists on aggressive behavior in rats". Pharmacol Biochem Behav.
15. (November 2007). "MDMA-like behavioral effects of N-substituted piperazines in the mouse". Pharmacol Biochem Behav.
16. (2001). "Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists". Pharmacol Biochem Behav.
17. (February 2005). "Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys". Drug Alcohol Depend.
18. "SOR/2012-65 March 30, 2012 Controlled Drugs and Substances Act". Government of Canada.
19. (27 September 2015). "关于印发《非药用类麻醉药品和精神药品列管办法》的通知". China Food and Drug Administration.
20. "FINLEX ® - Säädökset alkuperäisinä: Valtioneuvoston asetus kuluttajamarkkinoilta… 1129/2015".
21. "FINLEX ® - Säädökset alkuperäisinä: Valtioneuvoston asetus kuluttajamarkkinoilta… 225/2017".
22. "FINLEX ® - Säädökset alkuperäisinä: Valtioneuvoston asetus kuluttajamarkkinoilta… 733/2021".
23. "Misuse of Drugs (Classification of BZP) Amendment Bill 2008".
24. "Erowid TFMPP Vault : Legal Status". Erowid.
25. "RO 2010 4099". Fedlex.
26. "RO 2011 2595". Fedlex.
27. "§1308.11 Schedule I.".
28. "Scheduling Actions 2002". U.S. Department of Justice, Drug Enforcement Administration (DEA).
29. [http://leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/0893.html Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL]